title: Inhibition of nitrosation.
abstract: Humans are exposed through ingestion or inhalation to preformed N-nitroso compounds (NOC) in the environment and through the endogenous nitrosation of amino precursors in the body. Activated macrophages and bacterial strains isolated from human infections can enzymatically produce nitrosating agents and NOC from precursors at neutral pH. As a consequence, endogenous nitrosation may occur at various sites of the body, such as the oral cavity, stomach, urinary bladder, and at other sites of infection or inflammation. Numerous substances to which humans are exposed have been identified and shown to inhibit formation of NOC. Such inhibitors include vitamins C and E, certain phenolic compounds, and complex mixtures such as fruit and vegetable juices or other plant extracts. Nitrosation inhibitors normally destroy the nitrosating agents and, thus, act as competitors for the amino compound that serves as substrate for the nitrosating species. Independently, epidemiological studies have already established that fresh fruits and vegetables that are sources of vitamin C, other vitamins, and polyphenols have a protective effect against cancers at various sites and in particular gastric cancer. This article briefly reviews (a) the chemistry of NOC formation and inhibition; (b) the studies in experimental animals that showed that inhibition of endogenous NOC synthesis leads to a reduction of toxic, mutagenic, and carcinogenic effects; (c) recent studies in humans where the degree of inhibition of endogenous NOC synthesis was directly quantified; and (d) the possible contribution of nitrosation inhibitors to human cancer prevention.
authors.affiliation: Unit of Environmental Carcinogens and Host Factors, International Agency for Research on Cancer, Lyon, France.
authors.forename: H
authors.initials: H
authors.lastname: Bartsch
authors.forename: B
authors.initials: B
authors.lastname: Pignatelli
authors.forename: S
authors.initials: S
authors.lastname: Calmels
authors.forename: H
authors.initials: H
authors.lastname: Ohshima
mesh_terms: D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000494:pharmacology; D018281:Cholangiocarcinoma / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D004938:Esophageal Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D008262:Macrophage Activation; D008264:Macrophages / Q000201:enzymology; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D009603:Nitroso Compounds / Q000378:metabolism / Q000633:toxicity*; D009889:Opisthorchiasis / Q000150:complications; D010636:Phenols / Q000494:pharmacology; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D014810:Vitamin E / Q000494:pharmacology
chemical_list: D016587:Antimutagenic Agents; D009603:Nitroso Compounds; D010636:Phenols; D014810:Vitamin E; D001205:Ascorbic Acid